Literature DB >> 15322884

[Gordian knot: medication overuse headache].

Z Katsarava1, G Fritsche.   

Abstract

Overuse of any kind of headache drugs may lead to the development of the medication overuse headache (MOH). Clinical features of MOH depend on the substance class that has been overused. Overuse of analgesics leads to a chronic tension-type like headache, the overuse of triptans to daily migraine-like headache or to the increase of migraine frequency. The delay between the drug overuse and onset of daily headache is shortest for triptans (1.7 years), longer for ergots (2.7 years) and longest for analgesics (4.8 years). Treatment includes withdrawal followed by structured acute therapy and initiation of specific prophylactic treatment for the underlying primary headache. The relapse rate after a successful withdrawal is about 30%. Predictors for relapse are tension-type headache and the overuse of analgesics in combination with codeine, caffeine or opioids.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322884     DOI: 10.1007/s00482-004-0355-x

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  26 in total

1.  Incidence and predictors for chronicity of headache in patients with episodic migraine.

Authors:  Z Katsarava; S Schneeweiss; T Kurth; U Kroener; G Fritsche; A Eikermann; H-C Diener; V Limmroth
Journal:  Neurology       Date:  2004-03-09       Impact factor: 9.910

2.  Easy therapeutical management of sumatriptan-induced daily headache.

Authors:  H Göbel; H Stolze; A Heinze; M Dworschak
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

3.  Analgesic-induced chronic headache: long-term results of withdrawal therapy.

Authors:  H C Diener; J Dichgans; E Scholz; S Geiselhart; W D Gerber; A Bille
Journal:  J Neurol       Date:  1989-01       Impact factor: 4.849

4.  Drug-induced headache: long-term results of stationary versus ambulatory withdrawal therapy.

Authors:  B Suhr; S Evers; B Bauer; I Gralow; K H Grotemeyer; I W Husstedt
Journal:  Cephalalgia       Date:  1999-01       Impact factor: 6.292

5.  Butorphanol (Stadol): a study in problems of current drug information and control.

Authors:  M A Fisher; S Glass
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

6.  Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache?

Authors:  G G Tribl; P Schnider; C Wöber; S Aull; A Auterith; K Zeiler; P Wessely
Journal:  Cephalalgia       Date:  2001-07       Impact factor: 6.292

7.  Analgesic rebound headache in clinical practice: data from a physician survey.

Authors:  A Rapoport; P Stang; D L Gutterman; R Cady; H Markley; R Weeks; J Saiers; A W Fox
Journal:  Headache       Date:  1996-01       Impact factor: 5.887

8.  Clinical features of withdrawal headache following overuse of triptans and other headache drugs.

Authors:  Z Katsarava; G Fritsche; M Muessig; H C Diener; V Limmroth
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

9.  Drug abuse in chronic headache: a clinico-epidemiologic study.

Authors:  F Granella; S Farina; G Malferrari; G C Manzoni
Journal:  Cephalalgia       Date:  1987-03       Impact factor: 6.292

10.  Longterm prognosis of analgesic withdrawal in patients with drug-induced headaches.

Authors:  C Baumgartner; P Wessely; C Bingöl; J Maly; F Holzner
Journal:  Headache       Date:  1989-09       Impact factor: 5.887

View more
  2 in total

1.  [The role of opioids in the treatment of primary headache disorders].

Authors:  A Totzeck; C Gaul
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

Review 2.  [Ins and outs of neurologic therapy for chronic pain].

Authors:  S Sternberg; F Birklein; A May
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.